137 related articles for article (PubMed ID: 30210333)
41. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
Colditz J; Rupf B; Maiwald C; Baniahmad A
Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
[TBL] [Abstract][Full Text] [Related]
42. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
Kandil S; Westwell AD; McGuigan C
Bioorg Med Chem Lett; 2016 Apr; 26(8):2000-4. PubMed ID: 26965862
[TBL] [Abstract][Full Text] [Related]
43. Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens.
Avancès C; Georget V; Térouanne B; Orio F; Cussenot O; Mottet N; Costa P; Sultan C
Mol Cell Endocrinol; 2001 Nov; 184(1-2):13-24. PubMed ID: 11694337
[TBL] [Abstract][Full Text] [Related]
44. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
45. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.
Mizokami A; Koh E; Fujita H; Maeda Y; Egawa M; Koshida K; Honma S; Keller ET; Namiki M
Cancer Res; 2004 Jan; 64(2):765-71. PubMed ID: 14744796
[TBL] [Abstract][Full Text] [Related]
46. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model.
Hobisch A; Hoffmann J; Lambrinidis L; Eder IE; Bartsch G; Klocker H; Culig Z
Urol Int; 2000; 65(2):73-9. PubMed ID: 11025427
[TBL] [Abstract][Full Text] [Related]
47. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens.
Zhou J; Liu B; Geng G; Wu JH
Proteins; 2010 Feb; 78(3):623-37. PubMed ID: 19787772
[TBL] [Abstract][Full Text] [Related]
48. Discovery of novel androgen receptor antagonists: a hybrid approach of pharmacophore-based and docking-based virtual screening.
Liu J; Liu B; Guo G; Jing Y; Zhao G
Anticancer Drugs; 2015 Aug; 26(7):747-53. PubMed ID: 25933245
[TBL] [Abstract][Full Text] [Related]
49. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
[TBL] [Abstract][Full Text] [Related]
50. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor.
Song LN; Coghlan M; Gelmann EP
Mol Endocrinol; 2004 Jan; 18(1):70-85. PubMed ID: 14593076
[TBL] [Abstract][Full Text] [Related]
51. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
52. Novel Nor-Homo- and Spiro-Oxetan- Steroids Target the Human Androgen Receptor and Act as Antiandrogens.
Thiele M; Rabe S; Hessenkemper W; Roell D; Bartsch S; Kraft F; Abraham TE; Houtsmuller AB; van Royen ME; Giannis A; Baniahmad A
Curr Med Chem; 2015; 22(9):1156-1167. PubMed ID: 24934352
[TBL] [Abstract][Full Text] [Related]
53. Cheminformatics Driven Development of Novel Therapies for Drug Resistant Prostate Cancer.
Ban F; Dalal K; LeBlanc E; Morin H; Rennie PS; Cherkasov A
Mol Inform; 2018 Sep; 37(9-10):e1800043. PubMed ID: 29733509
[TBL] [Abstract][Full Text] [Related]
54. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
55. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
56. Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
Wu M; Xie Y; Cui X; Huang C; Zhang R; He Y; Li X; Liu M; Cen S; Zhou J
Eur J Med Chem; 2019 Mar; 166():232-242. PubMed ID: 30711833
[TBL] [Abstract][Full Text] [Related]
57. Androgen receptor modulators: a review of recent patents and reports (2012-2018).
Fujii S; Kagechika H
Expert Opin Ther Pat; 2019 Jun; 29(6):439-453. PubMed ID: 31092069
[TBL] [Abstract][Full Text] [Related]
58. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer.
Jiang C; Lee HJ; Li GX; Guo J; Malewicz B; Zhao Y; Lee EO; Lee HJ; Lee JH; Kim MS; Kim SH; Lu J
Cancer Res; 2006 Jan; 66(1):453-63. PubMed ID: 16397261
[TBL] [Abstract][Full Text] [Related]
59. Basic helix loop helix (bHLH) transcription factor 3 (TCF3, E2A) is regulated by androgens in prostate cancer cells.
Patel D; Chinaranagari S; Chaudhary J
Am J Cancer Res; 2015; 5(11):3407-21. PubMed ID: 26807321
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and pharmacological evaluation of novel arylpiperazine derivatives as nonsteroidal androgen receptor antagonists.
Kinoyama I; Taniguchi N; Yoden T; Koutoku H; Furutani T; Kudoh M; Okada M
Chem Pharm Bull (Tokyo); 2004 Nov; 52(11):1330-3. PubMed ID: 15516756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
